General Hospital Psychiatry
Volume 31, Issue 5 , Pages 403-413, September 2009

The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists☆☆

  • Kimberly A. Yonkers, M.D.

      Affiliations

    • Department of Psychiatry, Epidemiology and Public Health, Yale School of Medicine, New Haven, CT 06510, USA
    • Department of Obstetrics and Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA. Fax: +1 203 764 6766.
  • ,
  • Katherine L. Wisner, M.D., MS.

      Affiliations

    • Department of Psychiatry, Obstetrics and Gynecology, Women's Behavioral, HealthCARE, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    • Department of Reproductive Sciences, Epidemiology and Women's Studies, Women's Behavioral, HealthCARE, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
  • ,
  • Donna E. Stewart, M.D., FRCPC

      Affiliations

    • Departments of Psychiatry, Obstetrics and Gynecology, Family and Community Medicine, Medicine, Surgery and Anesthesia, University Health Network Women's Health Program, University of Toronto, Toronto, Ontario, Canada M5G 2C4
  • ,
  • Tim F. Oberlander, M.D., FRCPC

      Affiliations

    • Department of Pediatrics, University of British Columbia, Human Early Experience Unit, Centre for Community Child Health Research, Child and Family Research Institute, Vancouver, British Columbia, Canada V6 3V4
  • ,
  • Diana L. Dell, M.D., FACOG

      Affiliations

    • Duke University Medical Center, DUMC Box 3263, Durham, NC 27710, USA
  • ,
  • Nada Stotland, M.D., M.P.H.

      Affiliations

    • Department of Psychiatry and Obstetrics, Rush Medical College Chicago, IL 60637, USA
    • Department of Gynecology, Rush Medical College Chicago, IL 60637, USA
  • ,
  • Susan Ramin, M.D., FACOG

      Affiliations

    • The University of Texas Health Science Center at Houston, Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal–Fetal Medicine, Houston, TX 77030, USA
  • ,
  • Linda Chaudron, M.D., MS.

      Affiliations

    • Department of Psychiatry, Pediatrics and Obstetrics and Gynecology, University of Rochester, Rochester, NY 14642, USA
  • ,
  • Charles Lockwood, M.D., FACOG

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, PO Box 208063, New Haven, CT 06520-8063, USA

Received 10 February 2009; accepted 9 April 2009. published online 25 August 2009.

Abstract 

Objective

To address the maternal and neonatal risks of both depression and antidepressant exposure and develop algorithms for periconceptional and antenatal management.

Method

Representatives from the American Psychiatric Association, the American College of Obstetricians and Gynecologists and a consulting developmental pediatrician collaborated to review English language articles on fetal and neonatal outcomes associated with depression and antidepressant treatment during childbearing. Articles were obtained from Medline searches and bibliographies. Search keywords included pregnancy, pregnancy complications, pregnancy outcomes, depressive disorder, depressive disorder/dt, abnormalities/drug-induced/epidemiology, abnormalities/drug-induced/et. Iterative draft manuscripts were reviewed until consensus was achieved.

Results

Both depressive symptoms and antidepressant exposure are associated with fetal growth changes and shorter gestations, but the majority of studies that evaluated antidepressant risks were unable to control for the possible effects of a depressive disorder. Short-term neonatal irritability and neurobehavioral changes are also linked with maternal depression and antidepressant treatment. Several studies report fetal malformations in association with first trimester antidepressant exposure but there is no specific pattern of defects for individual medications or class of agents. The association between paroxetine and cardiac defects is more often found in studies that included all malformations rather than clinically significant malformations. Late gestational use of selective serotonin reuptake inhibitor antidepressants is associated with transitory neonatal signs and a low risk for persistent pulmonary hypertension in the newborn. Psychotherapy alone is an appropriate treatment for some pregnant women; however, others prefer pharmacotherapy or may require pharmacological treatment.

Conclusions

Antidepressant use in pregnancy is well studied, but available research has not yet adequately controlled for other factors that may influence birth outcomes including maternal illness or problematic health behaviors that can adversely affect pregnancy.

Keywords: Depression, Pregnancy, Antidepressant agents

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Yonkers has received a research grant from Eli Lilly this past year. She has received study drug from Pfizer for a National Institute of Mental Health trial. Dr. Stewart serves on the Advisory Boards of Wyeth and Eli Lilly and Boehringer Ingelheim. Dr. Dell has received research grants from Pfizer has consulted to Bayer Schering Pharma AG and Berlex and is on the Speaker's Bureau for Berlex, GlaxoSmithKline, Pfizer and Wyeth. Dr. Wisner serves on the Speaker's Board of Glaxo Smith Klein. Dr. Oberlander; Dr. Ramin; and Drs. Stotland, Chaudron, and Lockwood have no conflicts to disclose.

☆☆ This article is being published concurrently in the September 2009 issue of Obstetrics & Gynecology.

PII: S0163-8343(09)00061-9

doi:10.1016/j.genhosppsych.2009.04.003

General Hospital Psychiatry
Volume 31, Issue 5 , Pages 403-413, September 2009